Running for Support Dogs: A different kind of personalized medicine | Diaceutics

Running for Support Dogs: A different kind of personalized medicine

October 12th, 2017

When it came to accepting a challenge, Shilpa Haridas, Director of Operations at Diaceutics, went for the ‘ignorance is bliss’ approach and willingly signed up for the Great North Run in September 2017. This iconic event takes place in the North East of England and is now the world’s largest half marathon.

Shilpa had always enjoyed running and found it to be a calming activity but had never run the 13.1 mile distance before. So when colleague Andrea Jack suggested she run for the charity Support Dogs, how could she say no? After all, Andrea’s own support dog, Ruby, is a valued and much loved member of the Diaceutics team and we know what a difference she has made to everyday life for Andrea, who has psoriatic arthritis. Shilpa considered it an honour to run for such a good cause, but then she realised what she’d actually agreed to do.

Training got off to a good start but was interrupted by a period of frequent travel as Shilpa supported Diaceutics’ pharma clients. So when she was able to return to serious training in July there wasn’t much time left. However, everything went to plan and the weekend before the big race she completed her first 10 mile run.

For Shilpa, the Great North Run was an amazing experience. The support from not only the crowds but the other runners was truly uplifting, with runners encouraging each other along the course and even slowing down to keep pace with anyone struggling. She had hoped to complete the run in 2.5 hours but, after picking up an injury in the eighth mile, she bravely continued to a very impressive first time finish of 3 hours 3 minutes.

“It was a fantastic thing to be involved with, and even though I’d thought of it as a once in a lifetime event, I’d gladly do it again next year”, said Shilpa. Inspired by her first big race, she’s also hoping to run the Sheffield half marathon in 2018, again for Support Dogs – seeing as she raised a whopping £1000 they are bound to want her on their fundraising team.

Shilpa continues, “Support Dogs do fantastic work and can change people’s lives. Diaceutics works with pharma clients to help them integrate diagnostic tests for diseases such as epilepsy, an area in which a trained dog can be of huge benefit. It’s a different kind of personalized medicine than we usually encounter in a working day, but one where the effects are transforming.”

Well done Shilpa, from everyone at Diaceutics.

For more information on Ruby and the work of Support Dogs, click here:

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications